Athens General Children's Hospital Panagioti And Aglaia Kyriakou
- Address
- lock Available on a paid plan
Athens General Children's Hospital Panagioti And Aglaia Kyriakou - Pediatric Research Excellence
Athens General Children's Hospital Panagioti And Aglaia Kyriakou stands as a leading pediatric research institution dedicated to advancing treatment options for complex childhood diseases. The center specializes in innovative clinical trials spanning pediatric oncology, hematology, nephrology, gastroenterology, and respiratory conditions, with particular expertise in rare and life-threatening conditions affecting children from infancy through adolescence.
- Pediatric oncology including neuroblastoma, ependymoma, low-grade gliomas, rhabdomyosarcoma, and Langerhans cell histiocytosis
- Hematologic malignancies with focus on acute lymphoblastic leukemia treatment protocols for infants and children
- Chronic kidney disease research addressing anemia, proteinuria, and pruritus management in pediatric populations
- Respiratory disorders including asthma treatment optimization and vaccine development studies
The hospital demonstrates comprehensive capabilities across multiple medical disciplines, conducting studies from early phase dose-finding trials to large-scale international Phase 3 randomized controlled trials. Research initiatives encompass innovative approaches including immunotherapy, targeted molecular therapies, and maintenance strategies for complex conditions. The center's commitment extends to investigating growth disorders, metabolic conditions like obesity, neurological syndromes including epilepsy variants, and infectious disease prevention through vaccine studies, making it a cornerstone institution for pediatric clinical research in southeastern Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 17 therapeutic areas and 15 of 122 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 118 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Athens General Children's Hospital Panagioti And Aglaia Kyriakou
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 122 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 7 | Unknown | 2015-06-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.